PETS · Petmed Express Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · PETS

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$274.10M	$274.10M◇	$247.57M◇	-	-	-
Cost of Revenue	$157.84M	$202.42M	$185.84M	$195.34M	$219.27M	$202.88M
Gross Profit	$69.14M	$78.65M	$71.01M	$78.08M	$89.95M	$81.25M
R&D	-	-	-	-	-	-
SG&A	$38.65M	$55.25M	$49.47M	$30.83M	$28.29M	$25.26M
Total Operating Expenses	$70.67M	$86.81M	$72.44M	$52.37M	$52.36M	$50.27M
D&A	$7.04M	$7.06M	$3.55M	$2.74M	$2.43M	$2.26M
Operating Income	($1.53M)	($8.16M)	($1.43M)	$25.71M	$37.59M	$30.98M
Interest Expense	-	-	-	-	-	-
Income Tax	$5.68M	$1.19M	$1.35M	$5.97M	$8.61M	$8.04M
Net Income	($6.27M)	($7.46M)	$233.0K	$21.10M	$30.60M	$25.85M
EPS - Basic	($0.30)	($0.37)	$0.01	$1.05	$1.53	$1.29
EPS - Diluted	($0.30)	($0.37)	$0.01	$1.04	$1.52	$1.29

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$54.72M	$55.30M	$104.09M	$111.08M	$118.72M	$103.76M
Accounts Receivable	$2.32M	$3.28M	$1.74M	$1.91M	$2.59M	$3.84M
Inventory	$16.20M	-	-	-	-	-
Accounts Payable	$23.56M	$37.02M	$25.21M	$27.50M	$39.55M	$19.66M
Current Assets	$78.87M	$93.65M	$131.45M	$151.00M	$161.19M	$129.02M
Total Assets	$148.70M	$169.88M	$164.12M	$176.32M	$187.50M	$155.32M
Current Liabilities	$62.77M	$72.16M	$36.50M	$33.20M	$44.94M	$24.34M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$63.57M	$73.15M	$40.32M	$34.13M	$46.22M	$25.31M
Stockholders' Equity	$85.13M	$96.73M	$123.80M	$142.19M	$141.28M	$130.01M
Retained Earnings	$66.54M	$71.56M	$105.49M	$130.50M	$134.14M	$126.18M

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$4.72M	$4.32M	$27.80M	$18.50M	$40.08M	$38.84M
Investing Cash Flow	($5.11M)	($40.67M)	($10.26M)	($1.75M)	($2.43M)	($2.31M)
Financing Cash Flow	($181.0K)	($12.44M)	($24.54M)	($24.38M)	($22.69M)	($33.30M)
CapEx	$5.11M	$4.51M	$5.26M	$1.75M	$2.43M	$2.31M
Free Cash Flow	($395.0K)	($194.0K)	$22.54M	$16.75M	$37.64M	$36.53M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	25.2%	28.7%	28.7%	-	-	-
Operating margin	-0.6%	-3.0%	-0.6%	-	-	-
EBITDA margin	2.0%	-0.4%	0.9%	-	-	-
Net margin	-2.3%	-2.7%	0.1%	-	-	-
Free cash flow margin	-0.1%	-0.1%	9.1%	-	-	-
FCF / Net income	0.06	0.03	96.75	0.79	1.23	1.41
R&D / Revenue	-	-	-	-	-	-
SG&A / Revenue	14.1%	20.2%	20.0%	-	-	-
Effective tax rate	-	-	85.3%	22.1%	22.0%	23.7%
Return on assets	-4.2%	-4.4%	0.1%	12.0%	16.3%	16.6%
Return on equity	-7.4%	-7.7%	0.2%	14.8%	21.7%	19.9%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	1.26	1.30	3.60	4.55	3.59	5.30
Quick ratio	1.00	1.30	3.60	4.55	3.59	5.30
Cash ratio	0.87	0.77	2.85	3.35	2.64	4.26
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-	-	-	-	-	-
Equity multiplier	1.75	1.76	1.33	1.24	1.33	1.19
Liabilities / Assets	0.43	0.43	0.25	0.19	0.25	0.16
Efficiency
Asset turnover	1.84	1.61	1.51	-	-	-
Inventory turnover	9.74	-	-	-	-	-
Days sales outstanding	3d	4d	3d	-	-	-
Days inventory outstanding	37d	-	-	-	-	-
Days payable outstanding	54d	67d	50d	51d	66d	35d
Cash conversion cycle	-14d	-	-	-	-	-
Valuation
P / E	-	-	1624.0x	24.8x	23.1x	22.3x
P / B	1.0x	1.0x	2.7x	3.7x	5.0x	4.4x
P / S	0.3x	0.4x	1.3x	-	-	-
EV / EBITDA	5.7x	-	106.9x	14.6x	14.7x	14.2x
Growth
Revenue growth (YoY)	0.0%	10.7%	-	-	-	-
Revenue CAGR (3y)	-	-	-	-	-	-
Revenue CAGR (5y)	-	-	1.1%	-	-	-
Gross profit growth (YoY)	-12.1%	10.7%	-9.0%	-13.2%	10.7%	-14.8%
Operating income growth (YoY)	81.3%	-470.8%	-	-31.6%	21.3%	-32.9%
Net income growth (YoY)	16.0%	-	-98.9%	-31.1%	18.4%	-31.5%
EPS growth (YoY)	18.9%	-	-99.0%	-31.6%	17.8%	-29.9%
EPS CAGR (3y)	-	-	-80.2%	-17.3%	-5.8%	3.3%
EPS CAGR (5y)	-	-	-64.7%	-2.3%	8.3%	8.2%
FCF growth (YoY)	-103.6%	-	34.6%	-55.5%	3.0%	-17.9%
FCF CAGR (5y)	-	-	2.1%	-14.5%	109.9%	3.3%
Book value growth (YoY)	-12.0%	-21.9%	-12.9%	0.6%	8.7%	-3.5%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2026-03-31.

Business segments

$179.02M total

Reportable Segment$179.02M · 100.0%

Product / service

$4.50M total

Partner Program$4.50M · 100.0%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

2.83

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✗Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✓No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Retail-Drug Stores and Proprietary Stores

Company	Revenue (last FY)	Net margin	ROE
CVS	$402.07B	0.4%	2.4%
WBA	-	-	-
GRDN	$1.23B	-9.0%	-50.5%
MDVL	$43.11M	-110.5%	-228.7%
CVET	$4.58B	-1.2%	-3.6%

Comparing PETMED EXPRESS INC against the 5 most active filers in the same SIC group.

Dividends

$0.00/share trailing 12 months

Ex-date	Per share
Aug 11, 2023	$0.3000
Jun 5, 2023	$0.3000
Feb 16, 2023	$0.3000
Nov 17, 2022	$0.3000
Aug 11, 2022	$0.3000
May 19, 2022	$0.3000
Feb 4, 2022	$0.3000
Nov 5, 2021	$0.3000
Aug 5, 2021	$0.3000
May 13, 2021	$0.3000
Jan 29, 2021	$0.2800
Nov 6, 2020	$0.2800
Jul 30, 2020	$0.2800
May 14, 2020	$0.2800
Jan 31, 2020	$0.2700
Nov 1, 2019	$0.2700
Aug 1, 2019	$0.2700
May 16, 2019	$0.2700
Feb 1, 2019	$0.2700
Nov 2, 2018	$0.2700
Aug 2, 2018	$0.2700
May 17, 2018	$0.2500
Feb 2, 2018	$0.2500
Nov 3, 2017	$0.2000

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.